Overview

Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure

Status:
Terminated

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

The goal of the present study is to evaluate the best regimen for infliximab monotherapy, and to evaluate if limited combination therapy with IFX and an Immunomodulator for the first 6 months of therapy, in prior Immunomodulator failures, is superior to monotherapy with Immunomodulator cessation from the second infusion, in preventing loss of remission to IFX.

Phase:

Phase 4

Details

Lead Sponsor:

Prof. Arie Levine

Treatments:

6-Mercaptopurine
Adjuvants, Immunologic
Azathioprine
Immunologic Factors
Infliximab
Mercaptopurine
Methotrexate